S Sethi

Summary

Affiliation: University at Buffalo
Country: USA

Publications

  1. Sethi S, Mahler D, Marcus P, Owen C, Yawn B, Rennard S. Inflammation in COPD: implications for management. Am J Med. 2012;125:1162-70 pubmed publisher
    ..The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents. ..
  2. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355-65 pubmed publisher
  3. Parameswaran G, Wrona C, Murphy T, Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis. 2009;9:178 pubmed publisher
    ..catarrhalis as compared to colonization...
  4. Sethi S, Anzueto A, Farrell D. Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. Ann Clin Microbiol Antimicrob. 2005;4:5 pubmed
    ..These species are the predominant causative bacterial pathogens in AECB and thus the spectrum of activity of telithromycin makes it a potential alternative for the empirical treatment of AECB. ..
  5. Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35:1209-15 pubmed publisher
    ..Enhanced understanding of the host-pathogen interaction is needed to better prevent and treat respiratory tract infection in COPD. ..
  6. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic . Antimicrob Agents Chemother. 2005;49:153-60 pubmed
  7. request reprint
    Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant B, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:356-61 pubmed
    ..Bacterial concentrations are higher during exacerbation than during stable disease; however, these studies are cross sectional and devoid of strain typing...
  8. Sethi S, Jones P, Theron M, Miravitlles M, Rubinstein E, Wedzicha J, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10 pubmed publisher
    ..This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of these exacerbations...
  9. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2011;52 Suppl 4:S290-5 pubmed publisher

Detail Information

Publications9

  1. Sethi S, Mahler D, Marcus P, Owen C, Yawn B, Rennard S. Inflammation in COPD: implications for management. Am J Med. 2012;125:1162-70 pubmed publisher
    ..The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents. ..
  2. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355-65 pubmed publisher
  3. Parameswaran G, Wrona C, Murphy T, Sethi S. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis. 2009;9:178 pubmed publisher
    ..catarrhalis as compared to colonization...
  4. Sethi S, Anzueto A, Farrell D. Antibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitis. Ann Clin Microbiol Antimicrob. 2005;4:5 pubmed
    ..These species are the predominant causative bacterial pathogens in AECB and thus the spectrum of activity of telithromycin makes it a potential alternative for the empirical treatment of AECB. ..
  5. Sethi S. Infection as a comorbidity of COPD. Eur Respir J. 2010;35:1209-15 pubmed publisher
    ..Enhanced understanding of the host-pathogen interaction is needed to better prevent and treat respiratory tract infection in COPD. ..
  6. Sethi S, Breton J, Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic . Antimicrob Agents Chemother. 2005;49:153-60 pubmed
  7. request reprint
    Sethi S, Sethi R, Eschberger K, Lobbins P, Cai X, Grant B, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:356-61 pubmed
    ..Bacterial concentrations are higher during exacerbation than during stable disease; however, these studies are cross sectional and devoid of strain typing...
  8. Sethi S, Jones P, Theron M, Miravitlles M, Rubinstein E, Wedzicha J, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10 pubmed publisher
    ..This proof-of-concept study evaluates whether intermittent pulsed moxifloxacin treatment could reduce the frequency of these exacerbations...
  9. Sethi S. Molecular diagnosis of respiratory tract infection in acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis. 2011;52 Suppl 4:S290-5 pubmed publisher